Participated · Series E · Jun 2026

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Series C · Apr 2026

Adcendo is advancing a pipeline of first- and potential best-in-class antibody-drug conjugates, integrating novel targets and optimized linker-payload combinations. The company is progressing three ADC programs: ADCE-T02 (Tissue Factor) in a Phase I Tiffany-01 cohort expansion across multiple solid tumors, ADCE-D01 (uPARAP) in Phase 1 dose escalation and expansion for soft tissue sarcoma and other mesenchymal cancers, and ADCE-B05 (undisclosed target) in preclinical evaluation and planned dose escalation in squamous cell carcinomas. Founded in 2017, Adcendo is headquartered in Copenhagen with operations in Boston, Massachusetts, and is led by a team with extensive ADC development and commercialization experience. The recent $75 million Series C financing is intended to fund the programs through upcoming clinical milestones and data readouts. No revenue or other operating metrics were disclosed in the provided articles.

Led · Series C · Apr 2026

E2 is commercializing the Hēlo® Thrombectomy Platform, designed with a patented dual-action mechanism that integrates aspiration with mechanical clot disruption to deliver large-bore performance through a small-profile catheter. The system is indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature and supports injection, infusion, and aspiration during procedures. E2 describes the platform as intended to improve procedural efficiency and clinical performance as mechanical thrombectomy adoption grows. With the oversubscribed $80 million Series C, the company plans to scale its commercial organization and continue investments in research and operations. The company is backed by a syndicate including Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. New board members from the lead investors will join as the company advances commercialization.

Participated · Equity · Feb 2026

Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Participated · Series A · Dec 2025

Sidera Bio is an early-stage biotechnology company based in Denmark that has not yet publicly disclosed details of its therapeutic pipeline. Led by chief executive Keld Flintholm Jørgensen—formerly chief business officer at Lundbeck and a veteran of Roche—the startup is positioning itself as an ambitious new entrant in the Nordic life-sciences ecosystem. Although product specifics remain undisclosed, the company’s ability to attract a blue-chip investor syndicate suggests a focus on high-value therapeutic programs. The firm secured roughly 700 million Danish kroner ($109 million) in Series A capital, one of the largest early-stage biotech financings ever completed in Denmark. This sizeable war chest provides a multi-year runway to advance its R&D efforts and build a robust preclinical and clinical pipeline. The financing also signals growing international appetite for Scandinavian biotech innovation. With strong financial backing and experienced leadership, Sidera Bio is expected to accelerate hiring and expand laboratory operations as it moves its undisclosed programs toward key development milestones.